Introduction:
AbbVie commenced the construction of a new expansion at its Singapore manufacturing facility, emphasizing its commitment to patient care and the support of its burgeoning biologics pipeline.
Features:
It focuses on adding 24,000 liters of biologics drug-substance capacity to AbbVie's global network.
The expansion will create over 100 new jobs across various roles.
The facility serves markets worldwide with small-molecule and biologics manufacturing capabilities.
The expanded facility will employ over 500 people, covering manufacturing, quality assurance, supply chain, engineering, and administration roles.
Construction will begin later this year, with operations expected to start in 2026.
Specifications:
Name AbbVie
Type Expansion
Year 2026
